KR910007924A - 안티무스카린 기관지 확장제 - Google Patents

안티무스카린 기관지 확장제 Download PDF

Info

Publication number
KR910007924A
KR910007924A KR1019900016425A KR900016425A KR910007924A KR 910007924 A KR910007924 A KR 910007924A KR 1019900016425 A KR1019900016425 A KR 1019900016425A KR 900016425 A KR900016425 A KR 900016425A KR 910007924 A KR910007924 A KR 910007924A
Authority
KR
South Korea
Prior art keywords
compound
formula
pharmaceutically acceptable
imidazol
hydroxy
Prior art date
Application number
KR1019900016425A
Other languages
English (en)
Other versions
KR930004845B1 (ko
Inventor
에드워드 크로스 피터
스토비 알란
Original Assignee
데이비드 죤 우드
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이비드 죤 우드, 화이자 인코포레이티드 filed Critical 데이비드 죤 우드
Publication of KR910007924A publication Critical patent/KR910007924A/ko
Application granted granted Critical
Publication of KR930004845B1 publication Critical patent/KR930004845B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Feeding And Guiding Record Carriers (AREA)

Abstract

내용 없음

Description

안티무스카린 기관지 확장제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 일반식(I)의 화합물 및 이의 약제학적으로 허용되는 염.
    상기식에서, X는 (a) 할로, CF3, C1-C4알킬, C1-C4알콕시 및 하이드록시 중에서 각각 독립적으로 선택된 1개 또는 2개의 치환체에 의해 임의로 치환된 페닐 그룹 또는 (b)티에닐 그룹이고, Y는 탄소 또는 환 질소원자에의해 인접 탄소원자에 결합된 5-원 질소-함유 헤테로사이클릭 그룹이고 이미다졸일, 피라졸일, 트리아졸일 및 테트라졸일 중에서 선택되며, Y는 할로, CF3, C3-C4알콕시, 하이드록시 및 아미노 중에서 각각 독립적으로 선택된 1개 또는 2개의 치환체에 의해 임의로 치환된다.
  2. 제1항에 있어서, X가 (a) 1개 또는 2개의 플루오로 원자에 의해 임의로 치환된 페닐 그룹이거나 (b) 3-티에닐 그룹이고, Y는 제1항에서 정의한 바와 같은 비치환된 헤테로사이클릭 그룹인 화합물.
  3. 제2항에 있어서, X가 비치환된 그룹이고 Y는 1H-이미다졸-1-일, 1H-1,2,3-트리아졸-1-일, 1H-1,2,4-트리아졸-1-일, 1H-피라졸-1-일, 1H-테트라졸-1-일, 1H-이미다졸-4(5)-일, 1H-피라졸-4-일 또는 1H-피라졸-3(5)일인 화합물.
  4. 제3항에 있어서, Y가 1H-이미다졸-1-일인 화합물.
  5. 제1항 내지 4항중 어느 한 항에 있어서, 두개의 비대칭 중심 각각의 입체화학이 R배위를 갖는 하기 일반식(IA)의 화합물
  6. 제5항에 있어서, (2R,3'R)-3-퀴뉴클리디닐-3-하이드록시-2-(1H-이미다졸-1-일)-2-페닐프로판오에이트인 화합물.
  7. 제1항 내지 6항중 어느 한 항에 따른 일반식(I) 또는 (IA)의 화합물 또는 이의 약제학적으로 허용되는 염을 약제학적으로 허용되는 희석제 또는 담체와 함께 함유하는 약제학적 조성물.
  8. 제 1 항 내지 6 항중 어느 한 항에 있어서, 약제, 특히 만성 기도폐쇄질환(COAD)및 천식 치료용 약제에 사용하기 위한 일반식(I) 또는 (IA)의 화합물 또는 이의 약제학적으로 허용되는 염.
  9. 일반식(II)의 화합물 ;
    상기식에서, X및 Y는 제1항에서 정의한 바와 같다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900016425A 1989-10-19 1990-10-16 안티무스카린성 기관지 확장제 KR930004845B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898923590A GB8923590D0 (en) 1989-10-19 1989-10-19 Antimuscarinic bronchodilators
GB8923590.7 1989-10-19
GB89235907 1989-10-19

Publications (2)

Publication Number Publication Date
KR910007924A true KR910007924A (ko) 1991-05-30
KR930004845B1 KR930004845B1 (ko) 1993-06-09

Family

ID=10664848

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900016425A KR930004845B1 (ko) 1989-10-19 1990-10-16 안티무스카린성 기관지 확장제

Country Status (19)

Country Link
US (1) US5171744A (ko)
EP (1) EP0424021B1 (ko)
JP (1) JPH06780B2 (ko)
KR (1) KR930004845B1 (ko)
CN (1) CN1022488C (ko)
AT (1) ATE102198T1 (ko)
AU (1) AU616362B2 (ko)
CA (1) CA2027896A1 (ko)
DE (1) DE69007009T2 (ko)
FI (1) FI905147A0 (ko)
GB (1) GB8923590D0 (ko)
HU (1) HU206345B (ko)
NO (1) NO174256C (ko)
NZ (1) NZ235750A (ko)
PL (1) PL287365A1 (ko)
PT (1) PT95610A (ko)
RU (1) RU2005721C1 (ko)
YU (1) YU197290A (ko)
ZA (1) ZA908343B (ko)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205844T1 (de) * 1990-09-06 2001-10-15 Pfizer Anti-muscarin bronchodilatoren
GB9119705D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
FR2754261B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de quinuclidine, leur preparation et leur application en therapeutique
US5981549A (en) * 1997-02-14 1999-11-09 Synapse Pharmaceutical International Method for controlling or alleviating the symptoms of respiratory disease and allergies
AU762245B2 (en) * 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
JP2003089688A (ja) * 1998-12-25 2003-03-28 Mitsubishi-Tokyo Pharmaceuticals Inc イミダゾリン化合物
AU767877B2 (en) * 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2002051841A1 (en) 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
RU2282629C2 (ru) 2000-12-28 2006-08-27 Альмиралль Продесфарма Аг Производные хинуклидина, способ их получения и фармацевтическая композиция на их основе
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AP2007004238A0 (en) * 2003-10-14 2007-12-31 Glaxo Group Ltd Muscarinic acetycholine receptor antagonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
KR20090094460A (ko) * 2006-12-19 2009-09-07 아스트라제네카 아베 무스카린 수용체 길항제로서 퀴누클리디놀 유도체
DE602007011670D1 (de) 2007-01-10 2011-02-10 Irm Llc Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer
EA200901489A1 (ru) 2007-05-07 2010-04-30 Новартис Аг Органические соединения
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
KR20150011379A (ko) * 2007-05-30 2015-01-30 마이크로도스 테라퍼스, 인코포레이티드 옥시부티닌 투여를 위한 방법 및 조성물
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
AU2008334629B2 (en) 2007-12-10 2012-04-12 Novartis Ag Organic compounds
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
IN2012DN01453A (ko) 2009-08-20 2015-06-05 Novartis Ag
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
KR20130111968A (ko) * 2010-06-22 2013-10-11 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
ES2667424T3 (es) 2014-04-24 2018-05-10 Novartis Ag Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
US20220306617A1 (en) 2019-08-28 2022-09-29 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
US4644003A (en) * 1985-04-03 1987-02-17 Research Corporation 3-quinuclidinol esters, useful as antagonists of muscarinic acetylcholine receptors
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
IT1228288B (it) * 1989-01-09 1991-06-07 Zambon Spa Composti ad attivita' antiserotoninica

Also Published As

Publication number Publication date
HU206345B (en) 1992-10-28
PT95610A (pt) 1991-09-13
RU2005721C1 (ru) 1994-01-15
ZA908343B (en) 1992-06-24
GB8923590D0 (en) 1989-12-06
EP0424021B1 (en) 1994-03-02
EP0424021A1 (en) 1991-04-24
CA2027896A1 (en) 1991-04-20
CN1022488C (zh) 1993-10-20
CN1051041A (zh) 1991-05-01
FI905147A0 (fi) 1990-10-18
JPH03133980A (ja) 1991-06-07
YU197290A (sh) 1993-10-20
NO904523D0 (no) 1990-10-18
NO174256C (no) 1994-04-06
NO904523L (no) 1991-04-22
DE69007009T2 (de) 1994-06-09
AU6472690A (en) 1991-07-25
NO174256B (no) 1993-12-27
ATE102198T1 (de) 1994-03-15
HU906495D0 (en) 1991-04-29
NZ235750A (en) 1992-03-26
JPH06780B2 (ja) 1994-01-05
AU616362B2 (en) 1991-10-24
DE69007009D1 (de) 1994-04-07
HUT56365A (en) 1991-08-28
US5171744A (en) 1992-12-15
KR930004845B1 (ko) 1993-06-09
PL287365A1 (en) 1991-06-03

Similar Documents

Publication Publication Date Title
KR910007924A (ko) 안티무스카린 기관지 확장제
KR960704884A (ko) 항종양제 또는 항바이러스제로서의 디스타마이신 A 동족체 (Distamycin A analogues as antitumour or antiviral agents)
ES2118160T3 (es) Compuestos de azol, su produccion y su uso.
KR870004030A (ko) 축합 이미다조 피리딘 유도체
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
CA2316902A1 (en) Alpha-aminoamide derivatives useful as analgesic agents
SE8004194L (sv) 1-bensylimidazolderivat
TW200613297A (en) Pyrazole derivatives
RU2010122320A (ru) Новые производные 1, 3-дигидро-5-изобензофуранкарбонитрила и фармацевтическая композиция на их основе для лечения преждевременной эякуляции
KR960007592A (ko) 신규한 피롤로카바졸
CA2382247A1 (en) Azaindoles having serotonin receptor affinity
DE69332366T2 (de) Arylsubstituierte heterocyclische Verbindungen
DE69329184T2 (de) Alkylsubstituierte heterocyclische Verbindungen
KR890007741A (ko) 진통제
CA2549147A1 (en) Tricyclic 1-((3-indol-3-yl)carbonyl) piperazine derivatives as cannabinoid cb1 receptor agonists
KR900016201A (ko) 디아진 유도체와 그 제조방법 및 이를 함유하는 약제
KR890005068A (ko) 에탄온 옥심
KR890005085A (ko) 항진균제
KR890006654A (ko) 2-옥사-이소세펨 화합물, 이를 함유하는 조성물 및 이의 제조방법
KR850000456A (ko) 세팔로스포린 에스테르의 제조방법
KR830000249A (ko) 세파로스포린 화합물의 제조방법
KR890005096A (ko) 빈카민산 유도체
RU93005133A (ru) Производные азола, способ их получения, фармацевтическая композиция
KR890005071A (ko) 항진균제
KR900016124A (ko) 헤테로고리를 갖는 페닐카르복시산 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E801 Decision on dismissal of amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee